Project Grant R43HL184399
Award Date 8/15/26
Completion Date 7/14/27
Dollars Obligated $550K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Honolulu, HI 96821, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Icardio.ai Corporation $290,142 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, for an artificial intelligence-enabled diagnostic support system for echocardiography. Performance of the award concludes on August 31, 2027, at the recipient's location in Century City, California. The project addresses the shortage of trained echocardiographers and the infrastructure constraints that limit adoption of...
- The National Heart, Lung, and Blood Institute awarded Tele-Stethoscope Inc. $406,367 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop Phase I algorithms and demonstrate technical feasibility for a mobile phone–based diagnostic tool that uses acoustic data to predict clinically significant spirometry and echocardiogram findings. The recipient will develop algorithms for predicting FEV1 percent predicted findings using mobile phone–captured...
- The National Heart, Lung, and Blood Institute awarded Prenosis, Inc. $1,218,102 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the Heart Failure CardioScore, an artificial intelligence diagnostic tool for acute heart failure in emergency department patients. Prenosis will combine novel biomarkers and clinical data with machine learning to improve diagnostic and prognostic accuracy for acute heart failure, addressing the challenge...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- Federal Grant Award Summary Aventusoft LLC received a $500,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for June 30, 2026. The award supports late-stage development and commercialization readiness activities for HATS-OFF (HemotTag Assessment for Short-Term Outcomes of Heart Failure), a non-invasive hemodynamic monitoring device designed to detect heart...
- Federal Project Grant Summary Careevolution LLC received $498,576 in federal project grant funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period August 15, 2025 through July 31, 2026. The project, titled "Advancing TechQuity: Optimization of the FAITH! App for Dissemination to Promote Cardiovascular Health Among African Americans," involves enhancing a culturally tailored mobile health...